Vaxcyte Inc (NASDAQ: PCVX) — Company Overview, News & Financial Data
Vaxcyte develops next-generation vaccines to prevent infectious diseases, including candidates for pneumococcal and pertussis.
Vaxcyte Inc
Vaxcyte Inc is a clinical-stage vaccine innovation company focused on developing high-fidelity, broad-spectrum conjugate vaccines to prevent or treat bacterial infectious diseases. Utilizing a cell-free protein synthesis platform and site-specific protein conjugation technology, the company engineers vaccine candidates aimed at overcoming the limitations of conventional cell-based vaccine approaches. Its lead pipeline assets target invasive pneumococcal disease, including VAX-31 and VAX-24, as well as early-stage candidates targeting Group A Streptococcus, Shigella, and periodontitis. Headquartered in San Carlos, California, Vaxcyte maintains research, development, and biomanufacturing operations in the United States to support clinical production and commercial supply.
Snapshot
Operations
Products and/or services of Vaxcyte Inc
- Pneumococcal Conjugate Vaccine VAX-31: A 31-valent conjugate vaccine candidate engineered to protect adults and infants against invasive pneumococcal disease, offering broader serotype coverage than existing licensed vaccines and advancing through Phase 3 clinical development.
- Pneumococcal Conjugate Vaccine VAX-24: A 24-valent conjugate vaccine candidate developed to prevent invasive pneumococcal disease, completing clinical trials across adult and pediatric populations while demonstrating broad serotype immunogenicity and favorable safety profiles.
- Cell-Free Protein Synthesis Platform: An advanced biopharmaceutical platform utilizing cell-free protein expression and site-specific conjugation to produce multi-valent conjugate vaccines without the yield and structural limitations inherent to traditional cell-based manufacturing approaches.
- Group A Strep Vaccine Candidate: A preclinical vaccine candidate targeting Group A Streptococcus bacterial infections, designed to provide broad-spectrum protection against severe invasive disease, rheumatic heart disease, and acute pharyngitis in children and adults globally.
- Shigella Vaccine Candidate: A novel bioconjugate vaccine candidate under early-stage development to combat Shigella bacterial infections, aiming to prevent bacillary dysentery and severe endemic diarrheal disease in young children and high-risk populations.
- US Biomanufacturing Infrastructure: Clinical and commercial vaccine manufacturing operations located across the United States, including dedicated production capacity and a major biomanufacturing facility expansion in North Carolina to support future global supply demands.
Vaxcyte Inc executive team
- Mr. Grant E. Pickering M.B.A.Co-Founder, CEO & Director
- Mr. Andrew L. Guggenhime M.B.A.President & CFO
- Mr. James Wassil M.B.A., M.S.Executive VP & COO
- Mr. Mikhail Eydelman J.D.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- Dr. Jeff Fairman Ph.D.Co-Founder & VP of Research
- Ms. Whitney JonesChief People Officer
- Ms. Janet GraesserSenior Vice President of Corporate Affairs
- Mr. Harp Dhaliwal M.B.A.Chief Technical Operations Officer
- Sam IkiSenior Vice President of Project Management
- Ms. Elvia CowanSenior Vice President of Finance